A recent meta-analysis reported discordance rates of 20%, 33%, and 8% for ER, PR, and HER2 expression, respectively, between primary and metastatic lesions, with a notable trend of ER/PR loss during progression, especially in bone and liver metastases [ 22 ].
← all excerpts
Recurrent Hormone Receptor-Positive Breast Cancer With Multiple Sites of Distant Metastasis: A Case Report and Review of the Literature.
1
—
—